ERYTECH Pharma announced the allowance of a US patent application covering arginine deiminase (ADI) encapsulated into red blood cells for the treatment of arginase-1 deficiency (A1D), a debilitating rare metabolic disease
ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases
- Post author:Marianne Duparc
- Post published:February 8, 2022
- Post category:Newsroom